<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "12: potential net losses will", fill: "#8b008b"},
{source: "12: potential net losses will", target: "12: regulatory approval", fill: "#8b008b"},
{source: "12: regulatory approval", target: "12: United States or Europe ", fill: "#8b008b"},
{source: "12: United States or Europe ", target: "12: EFAPROXYN ", fill: "#8b008b"},
{source: "12: EFAPROXYN ", target: "12: brain metastases from breast cancer", fill: "#8b008b"},
{source: "12: potential net losses will", target: "13: generate revenue", fill: "#367588"},
{source: "13: generate revenue", target: "13: profitability", fill: "#367588"},
{source: "13: profitability", target: "13: dependent on", fill: "#367588"},
{source: "13: dependent on", target: "13: ability alone", fill: "#367588"},
{source: "13: ability alone", target: "13: with partners", fill: "#367588"},
{source: "13: with partners", target: "13: successfully", fill: "#367588"},
{source: "13: successfully", target: "13: development", fill: "#367588"},
{source: "13: development", target: "13: product candidates", fill: "#367588"},
{source: "13: product candidates", target: "13: product candidates conduct clinical trials", fill: "#367588"},
{source: "13: product candidates conduct clinical trials", target: "13: necessary", fill: "#367588"},
{source: "13: necessary", target: "13: regulatory approvals", fill: "#367588"},
{source: "13: regulatory approvals", target: "13: manufacture", fill: "#367588"},
{source: "13: generate revenue", target: "15: amounts on research", fill: "#98ff98"},
{source: "15: amounts on research", target: "15: development", fill: "#98ff98"},
{source: "15: development", target: "15: amounts spent on conducting clinical trials", fill: "#98ff98"},
{source: "15: amounts spent on conducting clinical trials", target: "15: candidates", fill: "#98ff98"},
{source: "15: amounts on research", target: "32: indications", fill: "#008080"},
{source: "32: indications", target: "32: relatively low incidence rates which", fill: "#008080"},
{source: "32: relatively low incidence rates which", target: "32: difficult", fill: "#008080"},
{source: "32: difficult", target: "32: clinical trials on", fill: "#008080"},
{source: "32: clinical trials on", target: "32: timely basis", fill: "#008080"},
{source: "32: timely basis", target: "32: product candidates", fill: "#008080"},
{source: "32: indications", target: "41: product candidates", fill: "#f64a8a"},
{source: "41: product candidates", target: "41: meet safety", fill: "#f64a8a"},
{source: "41: meet safety", target: "41: efficacy endpoints", fill: "#f64a8a"},
{source: "41: efficacy endpoints", target: "41: clinical trials", fill: "#f64a8a"},
{source: "41: clinical trials", target: "41: regulatory approval", fill: "#f64a8a"},
{source: "41: regulatory approval", target: "41: market them", fill: "#f64a8a"},
{source: "41: product candidates", target: "START_HERE", fill: "#f64a8a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial_management_system">Clinical trial management system</a></td>
      <td>A Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials in clinical research. The system maintains and manages planning, performing and reporting functions, along with participant contact information, tracking deadlines and milestones.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ALLOS THERAPEUTICS INC      ITEM 1A RISK FACTORS                  Our business <font color="blue">faces <font color="blue">significant</font> risks</font></td>
    </tr>
    <tr>
      <td>These risks include those     described  below  and may include <font color="blue"><font color="blue">additional</font> risks</font> of which we are not     currently aware or which we currently do not believe are material</td>
    </tr>
    <tr>
      <td>If any of     the events or <font color="blue"><font color="blue">circumstances</font> described</font> in the <font color="blue">following risk factors actually</font>     occurs, our business, <font color="blue">financial condition</font> and results of <font color="blue"><font color="blue">operations</font> could</font> be     <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risks should</font> be read in <font color="blue">conjunction</font>     with the other information set forth in this report</td>
    </tr>
    <tr>
      <td>We have a history of net losses and an <font color="blue"><font color="blue">accumulated</font> deficit</font>, and we     may never achieve or maintain revenue or <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>We  have  never  <font color="blue">generated <font color="blue">revenue from product sales</font></font> and have     experienced <font color="blue"><font color="blue">significant</font> net losses since</font> our inception in 1992</td>
    </tr>
    <tr>
      <td>To date, we     have  financed  our  <font color="blue">operations</font>  <font color="blue">primarily through</font> the <font color="blue">private sale</font> of     securities and our <font color="blue">initial public offering</font> of <font color="blue">common stock</font> in March 2000</td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31, 2003, 2004 and 2005, we had net losses of     dlra23dtta1 million,  dlra21dtta8 million,  and dlra20dtta8 million, respectively</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we have <font color="blue">accumulated</font> a deficit of dlra178dtta3 million during     our <font color="blue"><font color="blue">development</font> stage</font></td>
    </tr>
    <tr>
      <td>We have incurred these <font color="blue">losses principally from costs</font>     incurred in our research and <font color="blue"><font color="blue">development</font> programs</font> and from our general and     <font color="blue">administrative expenses</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">continue incurring net losses</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The presence and size of these <font color="blue">potential net losses will</font>     depend, in large part, on if and when we obtain <font color="blue"><font color="blue">regulatory</font> approval</font> in the     <font color="blue"><font color="blue">United States </font>or Europe </font>to market <font color="blue">EFAPROXYN </font>as an adjunct to radiation     therapy  for the treatment of <font color="blue">brain metastases from breast cancer</font></td>
    </tr>
    <tr>
      <td>Our     ability to <font color="blue">generate revenue</font> and achieve <font color="blue">profitability</font> is <font color="blue"><font color="blue">dependent</font> on</font> our     ability, alone or <font color="blue">with partners</font>, to <font color="blue">successfully</font> complete the <font color="blue">development</font> of     our  <font color="blue">product <font color="blue">candidates</font></font>, conduct <font color="blue"><font color="blue">clinical trial</font>s</font>, obtain the <font color="blue">necessary</font>     <font color="blue"><font color="blue">regulatory</font> approval</font>s, and <font color="blue">manufacture</font> and market our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We     may never <font color="blue">generate revenue</font> from product sales or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We     expect to continue to spend substantial <font color="blue">amounts on research</font> and <font color="blue">development</font>,     including  <font color="blue">amounts spent on conducting <font color="blue"><font color="blue">clinical trial</font>s</font></font> for our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">continue as</font> a going concern if we are     unable to <font color="blue">generate meaningful amounts</font> of revenue to support our <font color="blue">operations</font>     or <font color="blue">cannot otherwise raise</font> the <font color="blue">necessary</font> funds to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to find a <font color="blue">suitable successor</font> to <font color="blue">Michael E Hart </font>as     the Companyapstas President, <font color="blue">Chief Executive Officer </font>and Chief Financial Officer     in a <font color="blue">timely manner</font>, our business and results of <font color="blue">operations</font> may be harmed</td>
    </tr>
    <tr>
      <td>Hart has notified our <font color="blue">Board of Directors </font>of his intent to resign     his positions of President, <font color="blue">Chief Executive Officer </font>and Chief Financial     Officer  of  the  <font color="blue">Company  </font>once a successor <font color="blue">Chief Executive Officer </font>is     appointed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of Directors </font>has retained a <font color="blue">nationally</font> recognized     <font color="blue">executive search firm</font> to assist in the <font color="blue">recruitment</font> of a successor Chief     Executive Officer</td>
    </tr>
    <tr>
      <td>However, <font color="blue">competition</font> for <font color="blue">executive personnel</font> is intense,     and we may be unable to obtain a <font color="blue">suitable replacement</font> for Mr</td>
    </tr>
    <tr>
      <td>Hart in a     <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>Hart may choose to leave the     Company prior to his successor being appointed, in which case our business     and results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> are in <font color="blue">various stages</font> of <font color="blue">development</font> and may     never be fully developed in a <font color="blue">manner suitable</font> for <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>If we     do not develop <font color="blue"><font color="blue">commercially</font> successful products</font>, our ability to generate     <font color="blue">revenue will</font> be limited</td>
    </tr>
    <tr>
      <td>We currently have no products that are approved for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">product <font color="blue">candidates</font></font> are in <font color="blue">various stages</font> of <font color="blue">development</font>, and     <font color="blue">significant</font> research and <font color="blue">development</font>, financial resources and personnel will     be required to develop <font color="blue">commercially</font> viable products and obtain <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>A majority of our efforts and <font color="blue"><font color="blue">expenditure</font>s over</font> the next few     <font color="blue">years will</font> be devoted to <font color="blue">EFAPROXYN </font>Accordingly, our <font color="blue">future prospects</font> are     substantially <font color="blue"><font color="blue">dependent</font> on</font> obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> in the United     States or Europe to market <font color="blue">EFAPROXYN </font>as an adjunct to <font color="blue">radiation therapy</font> for     the treatment of <font color="blue">brain metastases originating from breast cancer</font></td>
    </tr>
    <tr>
      <td><font color="blue">EFAPROXYN </font>    is  not  expected  to  be <font color="blue">commercially</font> available for this or any other     <font color="blue">indication</font> until at least 2007</td>
    </tr>
    <tr>
      <td>In addition, PDX and                                         21       _________________________________________________________________       RH1 are in <font color="blue">earlier stages</font> of product <font color="blue">development</font> relative to EFAPROXYN, and     as such, we expect that PDX and RH1 will not be <font color="blue">commercially</font> available until     after  <font color="blue">EFAPROXYN </font> is  <font color="blue">commercially</font>  available</td>
    </tr>
    <tr>
      <td>Further, certain of the     <font color="blue"><font color="blue">indication</font>s</font> that we are pursuing have relatively low incidence rates, which     may make it <font color="blue">difficult</font> for us to enroll a sufficient number of patients in     our <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> on</font> a <font color="blue">timely basis</font>, or at all, and may limit the revenue     potential of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to develop, receive     approval for, or <font color="blue">successfully</font> <font color="blue">commercialize</font> any of our <font color="blue">product <font color="blue">candidates</font></font>,     we may be unable to <font color="blue">generate meaningful <font color="blue">revenue from product sales</font></font> and will     <font color="blue">incur continued net losses</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> when or if we will obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>A <font color="blue"><font color="blue">pharmaceutical</font> product cannot</font> be marketed in the <font color="blue">United States </font>or     most  other  countries until it has completed a rigorous and extensive     <font color="blue"><font color="blue">regulatory</font> approval</font> process</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to     market our <font color="blue">product <font color="blue">candidates</font></font>, we will be unable to sell our products and     <font color="blue">generate revenue</font>, which would jeopardize our ability to continue operating     our business</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of <font color="blue">regulatory</font> <font color="blue">requirements</font> typically takes many     years, is <font color="blue">dependent</font> upon the type, <font color="blue">complexity</font> and novelty of the product and     requires  the  <font color="blue">expenditure</font>  of  substantial  resources</td>
    </tr>
    <tr>
      <td>Of particular     significance  are  the <font color="blue">requirements</font> covering research and <font color="blue">development</font>,     testing, <font color="blue">manufacturing</font>, <font color="blue">quality control</font>, labeling and promotion of drugs for     human use</td>
    </tr>
    <tr>
      <td>We may not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for any <font color="blue">product <font color="blue">candidates</font></font>     we develop, including EFAPROXYN, or we may not obtain <font color="blue">regulatory</font> review of     such <font color="blue">product <font color="blue">candidates</font></font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>For a more complete description     of the <font color="blue"><font color="blue">regulatory</font> approval</font> process and related risks, please refer to the      &amp;quote <font color="blue">Government </font>Regulation &amp;quote  section of Item 1 above</td>
    </tr>
    <tr>
      <td>If our <font color="blue">product <font color="blue">candidates</font></font> do not <font color="blue">meet safety</font> and <font color="blue">efficacy <font color="blue">endpoints</font></font>     in <font color="blue"><font color="blue">clinical trial</font>s</font>, they will not receive <font color="blue"><font color="blue">regulatory</font> approval</font>, and we will     be unable to <font color="blue">market them</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> may not prove to be safe and <font color="blue">efficacious</font> in     clinical  trials  and  may  not  meet all of the applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font> needed to receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>The clinical <font color="blue">development</font>     and <font color="blue"><font color="blue">regulatory</font> approval</font> process is <font color="blue">extremely expensive</font> and takes many years</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>can  occur at any stage of <font color="blue">development</font>, and the timing of any     <font color="blue"><font color="blue">regulatory</font> approval</font> cannot be <font color="blue"><font color="blue">accurately</font> predicted</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for our current or future <font color="blue">product <font color="blue">candidates</font></font>, we will be     unable to market and sell them and <font color="blue">therefore may never</font> be profitable</td>
    </tr>
    <tr>
      <td>As part of the <font color="blue">regulatory</font> process, we must conduct <font color="blue"><font color="blue">clinical trial</font>s</font>     for  each  <font color="blue">product candidate</font> to <font color="blue"><font color="blue">demonstrate</font> safety</font> and efficacy to the     <font color="blue">satisfaction</font> of the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font> abroad</td>
    </tr>
    <tr>
      <td>The number     and design of <font color="blue"><font color="blue">clinical trial</font>s</font> that will be required <font color="blue">varies depending on</font> the     <font color="blue">product candidate</font>, the condition being evaluated, the trial results and     <font color="blue"><font color="blue">regulations</font> applicable</font> to any particular <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>For example,     <font color="blue">based on</font> the interim results from the Phase 1/2 study of PDX in patients     with  NHL  that  is  currently  ongoing, we plan to initiate a Phase 2     open-label,  multi-center  study  of  PDX in <font color="blue">patients with</font> relapsed or     <font color="blue">refractory</font> PTCL Given the <font color="blue">aggressive</font> nature of PTCL, the absence of an     approved  agent in this setting and the <font color="blue">relative size</font> of other Phase 2     studies that have <font color="blue">supported <font color="blue">marketing approval</font></font> for other <font color="blue">niche hematology</font>     drugs, such as nelarabine, we believe this Phase 2 trial, if positive, may     provide the basis to obtain <font color="blue">marketing approval</font> for PDX in this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you that the design of, or <font color="blue">data collected from</font>     this Phase 2 trial, or any of our other current or future <font color="blue"><font color="blue">clinical trial</font>s</font>,     we be sufficient to support FDA or any foreign <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>This     Phase 2 trial may not <font color="blue">demonstrate</font> the safety and efficacy of PDX for the     treatment of PTCL, or we may be required to conduct <font color="blue">additional</font> trials to     support <font color="blue"><font color="blue">regulatory</font> approval</font> of PDX in this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>The design of our <font color="blue"><font color="blue">clinical trial</font>s</font> is <font color="blue">based on</font> many <font color="blue">assumptions</font> about     the expected effect of our <font color="blue">product <font color="blue">candidates</font></font>, and if those <font color="blue">assumptions</font>     prove  incorrect,  the  clinical  <font color="blue">trials may</font> not produce <font color="blue">statistically</font>     <font color="blue">significant</font> results</td>
    </tr>
    <tr>
      <td><font color="blue">Preliminary </font>results may not be <font color="blue">confirmed upon</font> full     analysis  of the detailed results of a trial, and <font color="blue">prior <font color="blue">clinical trial</font></font>     <font color="blue">program designs</font> and results may not be predictive of <font color="blue">future <font color="blue">clinical trial</font></font>     designs or results</td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> in later stage <font color="blue"><font color="blue">clinical trial</font>s</font> may     fail to show                                         22       _________________________________________________________________       the desired safety and <font color="blue">efficacy despite</font> having progressed <font color="blue">through initial</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> with acceptable <font color="blue">endpoints</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">product <font color="blue">candidates</font></font> fail to     show  <font color="blue">clinically</font>  <font color="blue">significant</font>  benefits, they will not be approved for     marketing</td>
    </tr>
    <tr>
      <td>We may experience delays in our <font color="blue"><font color="blue">clinical trial</font>s</font>, including ENRICH,     that  <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">financial position</font> and our commercial     prospects</td>
    </tr>
    <tr>
      <td>We do not know when our current <font color="blue"><font color="blue">clinical trial</font>s</font>, including ENRICH,     will be completed, if at all</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot <font color="blue">accurately</font> predict</font> when other     planned <font color="blue"><font color="blue">clinical trial</font>s</font> will begin or be completed</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors affect</font>     patient  <font color="blue">enrollment</font>, including the size of the <font color="blue">patient population</font>, the     proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the     trial, competing <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">new drugs approved</font> for the <font color="blue">conditions</font>     we are <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>Other companies are conducting <font color="blue"><font color="blue">clinical trial</font>s</font> and     have announced plans for <font color="blue">future trials</font> that are seeking or likely to seek     <font color="blue">patients with</font> the <font color="blue">same diseases as</font> those we are studying</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for     patients  in some cancer trials is <font color="blue">particularly</font> intense because of the     limited  number  of  leading  <font color="blue">specialist physicians</font> and the geographic     <font color="blue">concentration</font> of <font color="blue">major clinical centers</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">numerous factors which</font> can affect the pace of     progress of <font color="blue"><font color="blue">clinical trial</font>s</font>, our <font color="blue">trials may</font> take longer to <font color="blue">enroll patients</font>     than we anticipate, if they can be completed at all</td>
    </tr>
    <tr>
      <td>Delays in patient     <font color="blue">enrollment</font>  in  the <font color="blue">trials may</font> increase our costs and slow our product     <font color="blue">development</font> and approval process</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> costs will also     increase if we need to perform more or larger <font color="blue"><font color="blue">clinical trial</font>s</font> than planned</td>
    </tr>
    <tr>
      <td>If other companies &amp;apos  <font color="blue">product <font color="blue">candidates</font></font> show favorable results, we may be     required  to  conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> to address changes in     treatment regimens or for our products to be <font color="blue">commercially</font> <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Any     delays in completing our <font color="blue"><font color="blue">clinical trial</font>s</font> will delay our ability to generate     <font color="blue">revenue from product sales</font>, and we may have insufficient <font color="blue">capital resources</font>     to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even if we do have sufficient <font color="blue">capital resources</font>,     our ability to <font color="blue">become profitable</font> will be delayed</td>
    </tr>
    <tr>
      <td>We may be required to suspend, repeat or terminate our clinical     trials, including ENRICH, if they are not conducted in <font color="blue"><font color="blue">accordance</font> with</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font>, the results are negative or <font color="blue">inconclusive</font> or the     trials are not <font color="blue">well designed</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials must</font> be conducted in <font color="blue"><font color="blue">accordance</font> with</font> the FDAapstas Good     Clinical Practices and are subject to oversight by the FDA and Institutional     Review Boards at the <font color="blue">medical <font color="blue">institutions</font></font> where the <font color="blue"><font color="blue">clinical trial</font>s</font> are     conducted</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">clinical trial</font>s</font> must be <font color="blue">conducted with product</font>     <font color="blue">candidates</font> produced under the FDAapstas <font color="blue">Good Manufacturing Practices</font>, and may     require large numbers of test subjects</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> be <font color="blue">suspended by</font>     the FDA or us at any time if it is believed that the subjects <font color="blue">participating</font>     in these trials are being exposed to unacceptable health risks or if <font color="blue">the FDA     </font><font color="blue">finds deficiencies</font> in the conduct of these trials</td>
    </tr>
    <tr>
      <td>Even if we achieve positive interim results in <font color="blue"><font color="blue">clinical trial</font>s</font>,     these results do not <font color="blue">necessarily predict final</font> results, and acceptable     results in early <font color="blue">trials may</font> not be repeated in <font color="blue">later trials</font></td>
    </tr>
    <tr>
      <td>Data obtained     from  preclinical  and  <font color="blue">clinical <font color="blue">activities</font></font> are susceptible to varying     <font color="blue">interpretations</font> that could delay, limit or prevent <font color="blue">regulatory</font> clearances,     and the FDA can request that we conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>A number     of  companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> have suffered <font color="blue">significant</font>     setbacks  in advanced <font color="blue"><font color="blue">clinical trial</font>s</font>, even after promising results in     <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>As a result, there can be no assurance that our ENRICH trial     will achieve its <font color="blue">primary endpoint</font></td>
    </tr>
    <tr>
      <td>In addition, negative or <font color="blue">inconclusive</font>     results or <font color="blue">adverse medical events during</font> a <font color="blue">clinical trial</font> could cause a     <font color="blue">clinical trial</font> to be repeated or terminated</td>
    </tr>
    <tr>
      <td>Also, failure to construct     clinical  trial  protocols to <font color="blue">screen patients</font> for <font color="blue">risk profile factors</font>     relevant to the trial for purposes of <font color="blue">segregating patients into</font> the patient     <font color="blue">populations treated with</font> the drug being tested and the control group could     result in either group experiencing a <font color="blue">disproportionate</font> number of adverse     events and could cause a <font color="blue">clinical trial</font> to be repeated or terminated</td>
    </tr>
    <tr>
      <td>If we     have to conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>, whether for <font color="blue">EFAPROXYN </font>or any     other <font color="blue">product candidate</font>, it would <font color="blue">significant</font>ly increase our expenses and     <font color="blue">delay marketing</font> of our products</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________               <font color="blue">Adverse  </font>events  in  our  <font color="blue"><font color="blue">clinical trial</font>s</font> may force us to stop     <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> or prevent <font color="blue"><font color="blue">regulatory</font> approval</font> of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> may produce <font color="blue">serious <font color="blue">adverse events</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">adverse events</font> could interrupt, delay or halt <font color="blue"><font color="blue">clinical trial</font>s</font> of our product     <font color="blue">candidates</font> and could result in the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font>     denying  approval  of  our  <font color="blue">product <font color="blue">candidates</font></font> for any or all targeted     <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>An in<font color="blue">dependent</font> data safety monitoring board, the FDA, other     <font color="blue">regulatory</font> <font color="blue">authorities</font> or we may suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at any     time</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our <font color="blue">product <font color="blue">candidates</font></font> will be safe     for human use</td>
    </tr>
    <tr>
      <td>Due to our reliance on contract research <font color="blue">organizations</font> and other     <font color="blue">third parties</font> to conduct <font color="blue"><font color="blue">clinical trial</font>s</font>, we are unable to <font color="blue">directly control</font>     the timing, conduct and expense of our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We rely primarily on <font color="blue">third parties</font> to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font>,     including the ENRICH trial</td>
    </tr>
    <tr>
      <td>As a result, we have had and <font color="blue">will continue</font> to     have less <font color="blue">control over</font> the conduct of our <font color="blue"><font color="blue">clinical trial</font>s</font>, the timing and     <font color="blue">completion</font> of the trials, the required reporting of <font color="blue">adverse events</font> and the     <font color="blue">management</font> of data developed through the <font color="blue">trial than would</font> be the case if we     were <font color="blue">relying entirely upon</font> our own staff</td>
    </tr>
    <tr>
      <td><font color="blue">Communicating </font><font color="blue">with outside parties</font>     can  also  be  <font color="blue">challenging</font>, potentially leading to <font color="blue">mistakes as well as</font>     <font color="blue">difficult</font>ies in <font color="blue">coordinating <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>Outside <font color="blue">parties may</font> have staffing     <font color="blue">difficult</font>ies, may undergo changes in priorities or <font color="blue">may become financially</font>     distressed, <font color="blue">adversely</font> affecting their <font color="blue">willingness</font> or ability to conduct our     trials</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">unexpected cost increases</font> that are beyond our     control</td>
    </tr>
    <tr>
      <td>Problems with the <font color="blue">timeliness</font> or quality of the work of a contract     <font color="blue">research organization may lead us</font> to seek to terminate the <font color="blue">relationship</font> and     use an <font color="blue">alternative service provider</font></td>
    </tr>
    <tr>
      <td>However, making this change may be     costly and may delay our trials, and <font color="blue">contractual <font color="blue">restrictions</font> may</font> make such     a change <font color="blue">difficult</font> or impossible</td>
    </tr>
    <tr>
      <td>Additionally, it may be impossible to find     a <font color="blue">replacement organization</font> that can conduct our trials in an acceptable     manner and at an acceptable cost</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">meet safety</font> and <font color="blue">efficacy <font color="blue">endpoints</font></font> in     <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">regulatory</font> <font color="blue">authorities</font> may not <font color="blue">approve them</font>, or we may face     post-approval problems that require withdrawal of our <font color="blue">products from</font> the     market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> may not be <font color="blue">approved even</font> if they achieve     their <font color="blue">endpoints</font> in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>agencies, including the FDA,     or  their  advisors may disagree with our <font color="blue">interpretations</font> of data from     preclinical  studies and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies also may</font>     approve a <font color="blue">product candidate</font> for fewer <font color="blue">conditions</font> than requested or may grant     approval subject to the performance of post-marketing studies for a product     candidate</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">regulatory</font> agencies may not approve the labeling     claims that are <font color="blue">necessary</font> or desirable for the successful <font color="blue">commercialization</font>     of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font>s, our <font color="blue">product <font color="blue">candidates</font></font> may     <font color="blue">later exhibit adverse effects</font> that limit or prevent their <font color="blue">widespread use</font> or     that force us to withdraw those <font color="blue">product <font color="blue">candidates</font></font> from the market</td>
    </tr>
    <tr>
      <td>In     addition, a <font color="blue">marketed product continues</font> to be subject to <font color="blue">strict regulation</font>     after approval and may be required to undergo post-approval studies</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">unforeseen problems with</font> an <font color="blue">approved product</font> or any violation of <font color="blue">regulations</font>     could result in <font color="blue"><font color="blue">restrictions</font> on</font> the product, including its <font color="blue">withdrawal from</font>     the market</td>
    </tr>
    <tr>
      <td>Any delay in, or failure to receive or maintain <font color="blue">regulatory</font>     approval for, any of our <font color="blue">products <font color="blue">could prevent</font> us from ever generating</font>     <font color="blue">meaningful revenues</font> or achieving <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">product <font color="blue">candidates</font></font>,     we will be subject to ongoing <font color="blue">regulatory</font> <font color="blue">obligations</font> and review</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>any <font color="blue"><font color="blue">regulatory</font> approval</font> of our <font color="blue">product <font color="blue">candidates</font></font>, we will     be subject to continuing <font color="blue">regulatory</font> <font color="blue">obligations</font> such as safety reporting     <font color="blue">requirements</font> and <font color="blue">additional</font> post-marketing <font color="blue">obligations</font>, including <font color="blue">regulatory</font>     oversight of the promotion and marketing of our products</td>
    </tr>
    <tr>
      <td>In addition, we or     our third-party <font color="blue">manufacture</font>rs will be required to adhere to <font color="blue">regulations</font>     <font color="blue">setting forth current</font> <font color="blue">Good Manufacturing Practices</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> cover     all aspects of the <font color="blue">manufacturing</font>, storage, testing,                                         24       _________________________________________________________________       <font color="blue">quality control</font> and record keeping relating to our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Furthermore, we or our third-party <font color="blue">manufacture</font>rs must pass a pre-approval     inspection of <font color="blue"><font color="blue">manufacturing</font> facilities by</font> the FDA and foreign <font color="blue">authorities</font>     before  obtaining  marketing  approval and will be subject to periodic     inspection by these <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">inspections</font> may result in     <font color="blue">compliance issues</font> that <font color="blue">could prevent</font> or delay <font color="blue">marketing approval</font>, or require     the <font color="blue">expenditure</font> of financial or other resources to address</td>
    </tr>
    <tr>
      <td>If we or our     third-party  <font color="blue">manufacture</font>rs  fail  to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font>,  we may be subject to fines, suspension or withdrawal of     <font color="blue">regulatory</font>  approvals, product recalls, seizure of products, operating     <font color="blue">restrictions</font> and <font color="blue">criminal <font color="blue">prosecution</font></font></td>
    </tr>
    <tr>
      <td>Budget <font color="blue">constraints may force us</font> to delay our efforts to develop     certain <font color="blue">product <font color="blue">candidates</font></font> in favor of developing others, which <font color="blue">may prevent</font>     <font color="blue">us from commercializing</font> all <font color="blue">product <font color="blue">candidates</font></font> as quickly as possible</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  have  limited resources, and because research and     <font color="blue">development</font> is an <font color="blue">expensive process</font>, we <font color="blue">must regularly assess</font> the most     <font color="blue">efficient allocation</font> of our research and <font color="blue">development</font> budget</td>
    </tr>
    <tr>
      <td>As a result, we     may have to prioritize <font color="blue">development</font> <font color="blue">candidates</font> and may not be able to fully     realize the value of some of our <font color="blue">product <font color="blue">candidates</font></font> in a <font color="blue">timely manner</font>, as     they will be delayed in reaching the market, if at all</td>
    </tr>
    <tr>
      <td>If we fail to obtain the capital <font color="blue">necessary</font> to fund our <font color="blue">operations</font>,     we will be unable to <font color="blue">successfully</font> develop or <font color="blue">commercialize</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">significant</font> <font color="blue">additional</font> capital will be required in     the  future  to  continue  our research and <font color="blue">development</font> efforts and to     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, if approved for marketing</td>
    </tr>
    <tr>
      <td>Our actual     capital <font color="blue">requirements</font> will depend on many factors, including, among other     factors:          •                 the timing and outcome of our ongoing ENRICH trial;          •                 costs associated with the <font color="blue">commercialization</font> of EFAPROXYN, if                 approved for marketing;          •                 our <font color="blue">evaluation</font> of, and <font color="blue">decisions with respect</font> to, our strategic                 <font color="blue">alternatives</font>, and          •                 costs  associated  with securing in-license <font color="blue">opportunities</font>,                 purchasing  product  <font color="blue">candidates</font> and <font color="blue">conducting preclinical</font>                 research and clinical <font color="blue">development</font> for our current and future                 <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We  intend  to  raise <font color="blue">additional</font> capital in the <font color="blue">future through</font>     <font color="blue">arrangements</font> with corporate partners, equity or <font color="blue">debt financings</font>, or from     other sources</td>
    </tr>
    <tr>
      <td>We do not know whether <font color="blue">additional</font> financing will be available     when  needed, or that, if available, we will obtain <font color="blue">financing on terms</font>     favorable to our <font color="blue">stockholders</font> or us</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available to     us, we will be required to delay, reduce the scope of or <font color="blue">eliminate one</font> or     more of our <font color="blue"><font color="blue">development</font> programs</font> and our business and <font color="blue">future prospects</font> for     revenue and <font color="blue">profitability</font> may be harmed</td>
    </tr>
    <tr>
      <td>To the extent we raise <font color="blue">additional</font>     capital  by issuing equity securities, our <font color="blue">stockholders</font> may experience     substantial dilution</td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue">additional</font> funds through     <font color="blue">collaboration</font> and licensing <font color="blue">arrangements</font>, we may be required to <font color="blue">relinquish</font>     some rights to our <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font>, or grant licenses on     terms that are not favorable to us</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">effective</font>ly protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font>,     we will be unable to prevent <font color="blue">third parties</font> from using our <font color="blue">technology</font>, which     <font color="blue">would impair</font> our <font color="blue"><font color="blue">competitive</font>ness</font> and ability to <font color="blue">commercialize</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, enforcing our <font color="blue"><font color="blue">proprietary rights</font> may</font> be expensive     and result in <font color="blue">increased losses</font></td>
    </tr>
    <tr>
      <td>Our  success  will depend in part on our ability to obtain and     maintain <font color="blue">meaningful <font color="blue">patent protection</font></font> for our products, both in the United     States and in other countries</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on patents</font> to protect a large part of     our <font color="blue"><font color="blue">intellectual</font> property</font> and our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">patents issued</font>     to  or  licensed  by  us  could be challenged, invalidated, infringed,     <font color="blue">circumvented</font> or held unenforceable</td>
    </tr>
    <tr>
      <td>In addition, it is possible that no     patents  will  issue on any of our <font color="blue">licensed patent <font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>It is     possible that the                                         25       _________________________________________________________________       claims in patents that have been issued or licensed to us or that may be     issued or licensed to us in the <font color="blue">future will</font> not be <font color="blue">sufficiently broad</font> to     protect our <font color="blue"><font color="blue">intellectual</font> property</font> or that the <font color="blue">patents will</font> not provide     protection  against  <font color="blue"><font color="blue">competitive</font> products</font> or otherwise be <font color="blue">commercially</font>     valuable</td>
    </tr>
    <tr>
      <td>Failure to obtain and maintain adequate <font color="blue">patent protection</font> for our     <font color="blue">intellectual</font>  property  would  impair  our  ability to be <font color="blue">commercially</font>     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">commercial success</font> will also depend</font> in part on our ability to     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> without infringing patents or other     <font color="blue">proprietary rights</font> of others or breaching the <font color="blue">licenses granted</font> to us</td>
    </tr>
    <tr>
      <td>We may     not  be able to obtain a license to third-party <font color="blue">technology</font> that we may     require to conduct our business or, if obtainable, we may not be able to     <font color="blue">license such <font color="blue">technology</font> at</font> a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain a license     to any <font color="blue">technology</font> that we may require to <font color="blue">commercialize</font> our <font color="blue">technologies</font> or     <font color="blue">product <font color="blue">candidates</font></font>, or fail to obtain a <font color="blue">license at</font> a <font color="blue">reasonable cost</font>, we     will be unable to <font color="blue">commercialize</font> the <font color="blue">affected product</font> or to <font color="blue">commercialize</font> it     at a price that <font color="blue">will allow us</font> to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we <font color="blue">also rely upon <font color="blue">trade secrets</font></font>,     proprietary know-how and <font color="blue"><font color="blue">technological</font> advances which</font> we seek to protect     <font color="blue">through <font color="blue">confidential</font>ity agreements with</font> our collaborators, employees and     <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Our employees and <font color="blue">consultants</font> are required to <font color="blue">enter into</font>     <font color="blue"><font color="blue">confidential</font>ity agreements with us</font></td>
    </tr>
    <tr>
      <td>We also have <font color="blue">entered into</font> non-disclosure     agreements, which are intended to protect our <font color="blue">confidential</font> information     delivered to <font color="blue">third parties</font> for research and other purposes</td>
    </tr>
    <tr>
      <td>However, these     <font color="blue">agreements could</font> be breached and we may not have <font color="blue">adequate remedies</font> for any     breach, or our <font color="blue">trade secrets</font> and proprietary know-how could otherwise become     known or be in<font color="blue">dependent</font>ly dis<font color="blue">covered by</font> others</td>
    </tr>
    <tr>
      <td>Furthermore, as with any <font color="blue"><font color="blue">pharmaceutical</font> company</font>, our patent and     other <font color="blue">proprietary rights</font> are subject to <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent rights</font>     related to our <font color="blue">product <font color="blue">candidates</font></font> might conflict with current or future     patents and other <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>For the same reasons, the     products of others could infringe our patents or other <font color="blue">proprietary rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or patent interference <font color="blue">proceedings</font>, either of <font color="blue">which could</font> result     in substantial costs to us, may be <font color="blue">necessary</font> to enforce any of our patents     or other <font color="blue">proprietary rights</font>, or to determine the scope and validity or     <font color="blue">enforceability</font>  of  other parties &amp;apos  <font color="blue">proprietary rights</font></td>
    </tr>
    <tr>
      <td>The defense and     <font color="blue">prosecution</font> of patent and <font color="blue"><font color="blue">intellectual</font> property</font> infringement claims are both     costly and time consuming, even if the outcome is favorable to us</td>
    </tr>
    <tr>
      <td>Any     adverse  outcome  could subject us to <font color="blue">significant</font> <font color="blue">liabilities</font> to third     parties, require <font color="blue">disputed rights</font> to be licensed from <font color="blue">third parties</font>, or     require us to <font color="blue">cease selling</font> our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>We are not currently a     party to any patent or other <font color="blue"><font color="blue">intellectual</font> property</font> infringement claims</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">manufacturing</font> facilities or <font color="blue">capabilities</font> and are     <font color="blue"><font color="blue">dependent</font> on</font> <font color="blue">third parties</font> to fulfill our <font color="blue">manufacturing</font> needs, <font color="blue">which could</font>     result  in the delay of <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue"><font color="blue">regulatory</font> approval</font>s, product     <font color="blue">introductions</font> and <font color="blue">commercial sale</font>s</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> <font color="blue">third parties</font> for the <font color="blue">manufacture</font> and storage of     our <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue"><font color="blue">clinical trial</font>s</font> and, if approved, for commercial     sale</td>
    </tr>
    <tr>
      <td>If we are unable to contract for a <font color="blue">sufficient supply</font> of our product     <font color="blue">candidates</font> on acceptable terms, or if we <font color="blue">encounter delays</font> or <font color="blue">difficult</font>ies in     the <font color="blue">manufacturing</font> process or our <font color="blue">relationship</font>s with our <font color="blue">manufacture</font>rs, we     may not have <font color="blue">sufficient product</font> to conduct or complete our <font color="blue"><font color="blue">clinical trial</font>s</font>     or support commercial <font color="blue">requirements</font> for our <font color="blue">product <font color="blue">candidates</font></font>, if approved</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">contract with</font> Hovione Inter Limited for the supply of     <font color="blue">EFAPROXYN </font>bulk drug substance, and a <font color="blue">contract with</font> <font color="blue">Baxter Healthcare </font>for the     supply  of  <font color="blue">EFAPROXYN </font><font color="blue">formulated drug product</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">manufacture</font>rs are     currently our <font color="blue">only contracted sources</font> for the production and <font color="blue">formulation</font> of     <font color="blue">EFAPROXYN </font>              Even  if we obtain approval to market <font color="blue">EFAPROXYN </font>in one or more     <font color="blue"><font color="blue">indication</font>s</font>, our current or future <font color="blue">manufacture</font>rs may be unable to <font color="blue">accurately</font>     and reliably <font color="blue">manufacture</font> commercial quantities of                                         26       _________________________________________________________________       <font color="blue">EFAPROXYN </font>at <font color="blue">reasonable cost</font>s, on a <font color="blue">timely basis</font> and in <font color="blue">compliance with</font> the     FDAapstas  current  <font color="blue">Good Manufacturing Practices</font></td>
    </tr>
    <tr>
      <td>If our current or future     contract <font color="blue">manufacture</font>rs fail in any of these respects, our ability to timely     complete our <font color="blue"><font color="blue">clinical trial</font>s</font>, obtain required <font color="blue"><font color="blue">regulatory</font> approval</font>s and     <font color="blue">successfully</font>  <font color="blue">commercialize</font> <font color="blue">EFAPROXYN </font>will be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our reliance on contract <font color="blue">manufacture</font>rs exposes us to <font color="blue">additional</font>     risks, including:          •                 delays or failure to <font color="blue">manufacture</font> sufficient quantities needed                 for <font color="blue"><font color="blue">clinical trial</font>s</font> in <font color="blue"><font color="blue">accordance</font> with</font> our <font color="blue">specifications</font> or to                 deliver <font color="blue">such quantities on</font> the dates we require;          •                 our current and future <font color="blue">manufacture</font>rs are subject to ongoing,                 periodic, unannounced <font color="blue">inspections</font> by the FDA and <font color="blue">corresponding</font>                 state and <font color="blue">international</font> <font color="blue">regulatory</font> <font color="blue">authorities</font> for compliance                 with strictly enforced current Good Manufacturing Practice                 <font color="blue">regulations</font> and similar foreign standards, and we do not have                 <font color="blue">control over</font> our contract <font color="blue">manufacture</font>rs &amp;apos  <font color="blue">compliance with</font> these                 <font color="blue">regulations</font> and standards;          •                 our current and future <font color="blue">manufacture</font>rs may not be able to comply                 with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, which would prohibit                 them from <font color="blue">manufacturing</font> products for us;          •                 if  we  need  to  change to other commercial <font color="blue">manufacturing</font>                 <font color="blue">contractors</font>, the FDA and comparable foreign <font color="blue">regulators</font> must                 approve these <font color="blue">contractors</font> prior to our use, which would require                 new  testing  and  compliance  <font color="blue">inspections</font>,  and  the  new                 <font color="blue">manufacture</font>rs  would have to be educated in, or <font color="blue">themselves</font>                 develop substantially equivalent processes <font color="blue">necessary</font> for, the                 production of our products;          •                 our <font color="blue">manufacture</font>rs might not be able to fulfill our commercial                 needs,  which  would  require us to seek new <font color="blue">manufacturing</font>                 <font color="blue">arrangements</font> and may result in substantial delays in meeting                 <font color="blue">market demands</font>; and          •                 we may not have <font color="blue"><font color="blue">intellectual</font> property</font> rights, or may have to                 share <font color="blue"><font color="blue">intellectual</font> property</font> rights, to any <font color="blue">improvements</font> in the                 <font color="blue">manufacturing</font> processes or new <font color="blue">manufacturing</font> processes for our                 products</td>
    </tr>
    <tr>
      <td>Any of these factors could result in the delay of <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">regulatory</font> submissions, required approvals or <font color="blue">commercialization</font> of our     products under <font color="blue">development</font>, entail higher costs and result in our being     unable to <font color="blue">effective</font>ly <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products in the marketplace is uncertain, and     failure to achieve <font color="blue">market <font color="blue">acceptance</font> will limit</font> our ability to generate     revenue and <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Even if approved for marketing, our <font color="blue">products may</font> not achieve market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The degree of market <font color="blue">acceptance</font> <font color="blue">will depend upon</font> a number of     factors, including:          •                 the receipt of timely <font color="blue"><font color="blue">regulatory</font> approval</font> for the uses that we                 are studying;          •                 the <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the <font color="blue">medical community</font> of                 the safety and efficacy of our products and their potential                 <font color="blue">advantages</font>  over  existing and newly developed <font color="blue">therapeutic</font>                 products;          •                 ease of use of our products;          •                 <font color="blue">reimbursement</font> and <font color="blue">coverage policies</font> of <font color="blue">government</font> and private                 payors  such  as  insurance  companies, health maintenance                 <font color="blue">organizations</font> and other plan <font color="blue">administrators</font>; and          •                 the scope and <font color="blue"><font color="blue">effective</font>ness</font> of our sales and <font color="blue">marketing efforts</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, payors or the <font color="blue">medical community</font> in <font color="blue">general may</font>     be unwilling to accept, utilize or recommend the use of any of our products</td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________               The  status of <font color="blue">reimbursement</font> from third-party payors for newly     <font color="blue">approved <font color="blue">health care</font> drugs</font> is uncertain and failure to obtain adequate     <font color="blue">reimbursement</font> could limit our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">products will</font> depend,     in part, on the extent to which <font color="blue">reimbursement</font> for the <font color="blue">products will</font> be     <font color="blue">available from</font>:          •                 <font color="blue">government</font> and health administration <font color="blue">authorities</font>;          •                 <font color="blue">private health insurers</font>;          •                 <font color="blue">managed care programs</font>; and          •                 other third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of     <font color="blue">newly approved <font color="blue">health care</font> products</font></td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare,     are  <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other third-party payors increasingly are attempting to     contain  health  <font color="blue">care costs by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> for new drugs and by refusing, in some cases, to provide     coverage for uses of <font color="blue">approved product</font>s for disease <font color="blue">conditions</font> for which the     FDA has not <font color="blue">granted labeling approval</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">insurance coverage may</font>     not be available to patients for our products</td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and other     third-party payors do not <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels     for our <font color="blue">product <font color="blue">candidates</font></font>, their market <font color="blue">acceptance</font> may be reduced</td>
    </tr>
    <tr>
      <td>Health care reform measures <font color="blue">could <font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>The  business  and  financial  condition of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies are <font color="blue">affected by</font> the efforts of <font color="blue">government</font>al and     third-party payors to contain or reduce the costs of <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>In the     <font color="blue">United States </font>and in <font color="blue">foreign jurisdictions there</font> have been, and we expect     that <font color="blue">there <font color="blue">will continue</font></font> to be, a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font>     <font color="blue">proposals aimed at</font> changing the <font color="blue">health care</font> system</td>
    </tr>
    <tr>
      <td>For example, in some     countries other than the United States, pricing of <font color="blue">prescription drugs</font> is     subject to <font color="blue">government</font> control, and we expect proposals to implement similar     controls in the <font color="blue">United States </font>to continue</td>
    </tr>
    <tr>
      <td>We are unable to predict what     <font color="blue">additional</font> <font color="blue">legislation</font> or regulation, if any, relating to the <font color="blue">health care</font>     industry or third-party coverage and <font color="blue">reimbursement</font> may be enacted in the     future or what effect <font color="blue">such <font color="blue">legislation</font></font> or <font color="blue">regulation would</font> have on our     business</td>
    </tr>
    <tr>
      <td>The pendency or approval of <font color="blue">such proposals</font> or <font color="blue">reforms could</font> result     in a decrease in our stock price or limit our ability to <font color="blue">raise capital</font> or to     obtain <font color="blue">strategic partnerships</font> or licenses</td>
    </tr>
    <tr>
      <td>The  FDA  has  designated <font color="blue">EFAPROXYN </font>for the treatment of brain     <font color="blue">metastases from breast cancer as</font> an <font color="blue"><font color="blue">orphan drug</font> under</font> the <font color="blue">Orphan Drug Act</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">Orphan Drug Act</font> <font color="blue">provides incentives</font> to <font color="blue">pharmaceutical</font> companies to     develop and <font color="blue">market drugs</font> for rare diseases, generally by entitling the first     developer that receives FDA <font color="blue">marketing approval</font> for an <font color="blue">orphan drug</font> to a     seven-year exclusive marketing period in the <font color="blue">United States </font>for that product</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, <font color="blue">Congress </font>has considered <font color="blue">legislation</font> to change the Orphan     Drug Act to shorten the period of automatic market <font color="blue">exclusivity</font> and to grant     <font color="blue">marketing rights</font> to <font color="blue">simultaneous developers</font> of a drug</td>
    </tr>
    <tr>
      <td>If the Orphan Drug     Act is amended in this manner, any <font color="blue">approved drugs</font> for which we have been     granted exclusive <font color="blue">marketing rights</font> under the <font color="blue">Orphan Drug Act</font> will face     increased <font color="blue">competition</font>, which may decrease the amount of revenue we may     receive from these products</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to  develop  adequate sales, marketing or     <font color="blue">distribution</font> <font color="blue">capabilities</font> or <font color="blue">enter into</font> agreements with <font color="blue">third parties</font> to     perform some of these functions, we will not be able to <font color="blue">commercialize</font> our     <font color="blue">products <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>We have limited experience in sales, marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>To     <font color="blue">directly market</font> and distribute any products, we must build a sales and     marketing organization with <font color="blue">appropriate</font> technical expertise and <font color="blue">distribution</font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We  may  attempt  to  build  such a sales and marketing     organization on our                                         28       _________________________________________________________________       own or with the assistance of a <font color="blue">contract sales organization</font></td>
    </tr>
    <tr>
      <td>For some market     <font color="blue">opportunities</font>, we may need to <font color="blue">enter into</font> co-promotion or other licensing     <font color="blue">arrangements</font> with larger <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font> firms in order to     increase the likelihood of <font color="blue">commercial success</font> for our products</td>
    </tr>
    <tr>
      <td>We may not     be able to establish sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font> of our     own or <font color="blue">enter into</font> such <font color="blue">arrangements</font> with <font color="blue">third parties</font> in a <font color="blue">timely manner</font> or     on acceptable terms</td>
    </tr>
    <tr>
      <td>To the extent that we <font color="blue">enter into</font> co-promotion or other     licensing <font color="blue">arrangements</font>, our <font color="blue">product revenues</font> are likely to be lower than if     we <font color="blue">directly market</font>ed and sold our products, and some or all of the revenues     we receive <font color="blue">will depend upon</font> the efforts of <font color="blue">third parties</font>, and these efforts     may not be successful</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">building marketing</font> and <font color="blue">distribution</font>     <font color="blue">capabilities</font> may be more <font color="blue">expensive than</font> we anticipate, requiring us to     <font color="blue">divert capital from</font> other <font color="blue">intended purposes</font> or <font color="blue">preventing us from building</font>     our marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font> to the desired levels</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">competitors</font> develop and <font color="blue">market products</font> that are more     <font color="blue">effective</font>  than  ours,  our  <font color="blue">commercial opportunity will</font> be reduced or     eliminated</td>
    </tr>
    <tr>
      <td>Even if we obtain the <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s to market     <font color="blue">EFAPROXYN </font>or any other <font color="blue">product <font color="blue">candidates</font></font>, our <font color="blue">commercial opportunity will</font>     be reduced or eliminated if our <font color="blue">competitors</font> develop and <font color="blue">market products</font> that     are more <font color="blue">effective</font>, have fewer side effects or are less <font color="blue">expensive than</font> our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our potential <font color="blue">competitors</font> include large <font color="blue">fully integrated</font>     <font color="blue">pharmaceutical</font> companies and more established bio<font color="blue">technology</font> companies, both     of  which  have  <font color="blue">significant</font>  resources  and expertise in research and     <font color="blue">development</font>, <font color="blue">manufacturing</font>, testing, obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s and     marketing</td>
    </tr>
    <tr>
      <td><font color="blue">Academic </font><font color="blue">institutions</font>, <font color="blue">government</font> agencies, and other public and     private research <font color="blue">organizations</font> conduct research, seek <font color="blue">patent protection</font> and     establish   <font color="blue">collaborative</font>   <font color="blue">arrangements</font>  for  research,  <font color="blue">development</font>,     <font color="blue">manufacturing</font> and marketing</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">competitors</font> will succeed in     developing <font color="blue">technologies</font> that are more <font color="blue">effective</font> than those being developed     by us or that would render our <font color="blue">technology</font> obsolete or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font> are <font color="blue">successfully</font> brought against us,     we  may  incur  substantial  <font color="blue">liabilities</font>  and may be required to limit     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The testing and marketing of <font color="blue">pharmaceutical</font> products entail an     inherent  risk of <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims might be     brought against us by consumers, <font color="blue">health care</font> providers or by <font color="blue">pharmaceutical</font>     companies or <font color="blue">others selling</font> our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font>     <font color="blue">defend ourselves against such</font> claims, we may incur substantial <font color="blue">liabilities</font>     or be required to limit the <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We     have obtained limited <font color="blue">product <font color="blue">liability</font></font> insurance coverage for our human     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">product <font color="blue">liability</font></font> insurance coverage is becoming     <font color="blue">increasingly expensive</font>, and we may be unable to maintain <font color="blue">product <font color="blue">liability</font></font>     <font color="blue">insurance coverage at</font> a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to protect     <font color="blue">us against losses due</font> to <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>A successful <font color="blue">product <font color="blue">liability</font></font>     claim in excess of our <font color="blue">insurance coverage could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We     may  not  be  able to obtain <font color="blue">commercially</font> reasonable <font color="blue">product <font color="blue">liability</font></font>     insurance for any <font color="blue">products approved</font> for marketing</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently involved</font> in a securities class <font color="blue">action <font color="blue">litigation</font></font>,     <font color="blue">which could</font> harm our business if <font color="blue">management</font> attention is diverted or the     claims are <font color="blue">decided against us</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">been named as</font> a <font color="blue">defendant</font> in an alleged securities class     <font color="blue">action lawsuit seeking unspecified damages</font> relating to the issuance of     <font color="blue">allegedly false</font> and <font color="blue">misleading statements</font> regarding <font color="blue">EFAPROXYN </font>during the     <font color="blue">period from</font> May 29, 2003 to April 29, 2004 and <font color="blue">subsequent declines</font> in our     stock price</td>
    </tr>
    <tr>
      <td>On October 20, 2005, the <font color="blue">District Court </font>granted our motion to     dismiss the <font color="blue">lawsuit with prejudice</font> and <font color="blue">entered judgment</font> in our favor</td>
    </tr>
    <tr>
      <td>On     November 20, 2005, the <font color="blue">plaintiff appealed</font> the decision to the <font color="blue">United States </font>    Court  of  Appeals  for the Tenth Circuit</td>
    </tr>
    <tr>
      <td>We are currently engaged in     <font color="blue">defending against</font> these claims, which, if <font color="blue">decided against us</font>, could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">costs incurred</font> in <font color="blue"><font color="blue">connection</font> with</font> this <font color="blue">lawsuit could</font> be     <font color="blue">significant</font> and may not be <font color="blue">covered by</font> our <font color="blue">insurance policies</font></td>
    </tr>
    <tr>
      <td>This lawsuit     <font color="blue">could also</font>                                         29       _________________________________________________________________       result in <font color="blue">continued diversion</font> of our time and <font color="blue">attention away from</font> business     <font color="blue">operations</font>, <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to attract, retain and motivate skilled personnel and     cultivate key academic <font color="blue">collaboration</font>s will delay our product <font color="blue">development</font>     programs and our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We are a small company with 57 full-time employees, and our success     <font color="blue">depends on</font> our <font color="blue">continued ability</font> to attract, retain and <font color="blue">motivate highly</font>     qualified <font color="blue">management</font> and <font color="blue">scientific personnel</font> and on our ability to develop     and maintain important <font color="blue">relationship</font>s with leading academic <font color="blue">institutions</font> and     <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font> for personnel and academic <font color="blue">collaboration</font>s is     intense</td>
    </tr>
    <tr>
      <td>In particular, our product <font color="blue"><font color="blue">development</font> programs</font> depend on our     ability to attract and retain highly skilled clinical <font color="blue">development</font> personnel</td>
    </tr>
    <tr>
      <td>In  addition,  we  will  need to hire <font color="blue">additional</font> personnel and develop     <font color="blue">additional</font> academic <font color="blue">collaboration</font>s as we continue to expand our research and     <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We do not know if we will be able to attract, retain     or  motivate  personnel  or  maintain  our <font color="blue">relationship</font>s with academic     <font color="blue">institutions</font> and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>If we fail to negotiate <font color="blue">additional</font> acceptable     <font color="blue">collaboration</font>s with academic <font color="blue">institutions</font> and <font color="blue">scientists</font>, or if our existing     academic <font color="blue">collaboration</font>s were to be <font color="blue">unsuccessful</font>, our product <font color="blue">development</font>     <font color="blue">programs may</font> be delayed</td>
    </tr>
    <tr>
      <td>We  cannot  guarantee  that  we will be in <font color="blue">compliance with</font> all     potentially applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font>,  <font color="blue">manufacturing</font>,  and,  if approved, pricing,     marketing,  sales and <font color="blue">reimbursement</font> of our products, together with our     general <font color="blue">obligations</font>, are subject to extensive <font color="blue">regulation by federal</font>, state     and other <font color="blue">authorities</font> within the <font color="blue">United States </font>and numerous entities outside     <font color="blue">of the United States</font></td>
    </tr>
    <tr>
      <td>We also have <font color="blue">significant</font>ly fewer employees than many     other companies that have the same or fewer <font color="blue">product <font color="blue">candidates</font></font> in late stage     clinical <font color="blue">development</font> and we rely heavily on <font color="blue">third parties</font> to conduct many     <font color="blue">important functions</font></td>
    </tr>
    <tr>
      <td>As  a  publicly-traded  company, we are subject to <font color="blue">significant</font>     <font color="blue">regulations</font>, some of which have either only recently been adopted, including     the  <font color="blue">Sarbanes Oxley Act </font>of 2002, or are currently proposals subject to     change</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we are or will be in <font color="blue">compliance with</font> all     potentially applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> the Sarbanes     Oxley Act of 2002 or any other <font color="blue">regulations</font> we could be subject to a range of     <font color="blue">consequences</font>,  including <font color="blue"><font color="blue">restrictions</font> on</font> our ability to <font color="blue">sell equity</font> or     otherwise <font color="blue">raise capital</font> funds, the de-listing of our <font color="blue">common stock</font> from the     Nasdaq National Market, suspension or <font color="blue">termination</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font>,     failure to obtain approval to market our <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue"><font color="blue">restrictions</font> on</font>     <font color="blue">future products</font> or our <font color="blue">manufacturing</font> processes, <font color="blue">significant</font> fines, or other     sanctions or <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Warburg Pincus Private Equity VIII, LP ( &amp;quote Warburg &amp;quote ) controls a     substantial percentage of the <font color="blue">voting power</font> of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>On March 2, 2005, we <font color="blue">entered into</font> a <font color="blue">Securities Purchase Agreement     </font>with Warburg Pincus Private Equity VIII, LP ( &amp;quote Warburg &amp;quote ) and certain other     <font color="blue">investors pursuant</font> to which we issued and sold an aggregate of 2cmam352cmam443     shares of our <font color="blue">Series A <font color="blue">Exchangeable Preferred</font> Stock </font>(the  &amp;quote Exchangeable     Preferred &amp;quote ) at a price per share of dlra22dtta10, for aggregate gross proceeds of     approximately dlra52dtta0 million</td>
    </tr>
    <tr>
      <td>On May 18, 2005, at our <font color="blue">Annual Meeting </font>of     Stockholders, our <font color="blue">stockholders</font> voted to approve the issuance of shares of     our <font color="blue">common stock</font> upon exchange of shares of the <font color="blue">Exchangeable Preferred</font></td>
    </tr>
    <tr>
      <td>As a     result of such approval, we issued a total of 23cmam524cmam430 shares of common     stock upon exchange of 2cmam352cmam443 shares of <font color="blue">Exchangeable Preferred</font> (the      &amp;quote <font color="blue">Share Exchange </font>&amp;quote )</td>
    </tr>
    <tr>
      <td>After giving effect to the Share Exchange, the <font color="blue">Company  </font>   has approximately 55dtta1 million shares of <font color="blue">common stock</font> outstanding as of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Warburg owns approximately 22dtta6 million shares of our     <font color="blue">common stock</font>, or 41prca of the <font color="blue">voting power</font> of our outstanding <font color="blue">common stock</font> as     of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>As a result, Warburg is able to exercise substantial     <font color="blue">influence over</font> any actions requiring <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>However, in     <font color="blue"><font color="blue">connection</font> with</font> its purchase of the <font color="blue">Exchangeable Preferred</font>, Warburg entered     into a <font color="blue">standstill agreement agreeing</font> not to pursue, for four years, certain     <font color="blue">activities</font> the purpose or effect of which may be to change or influence the     control of Allos</td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________               Anti-takeover provisions in our <font color="blue">charter documents</font> and under <font color="blue"><font color="blue">Delaware </font>    </font>law could discourage, delay or prevent an <font color="blue">acquisition</font> of us, even if an     <font color="blue">acquisition</font>  would  be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, and <font color="blue">may prevent</font>     <font color="blue">attempts by</font> our <font color="blue">stockholders</font> to replace or remove our current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font>     and  bylaws, as well as provisions <font color="blue">of <font color="blue">Delaware </font></font>law, could make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us, even if doing so <font color="blue">would benefit</font>     our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">provisions may frustrate</font> or prevent any     <font color="blue">attempts by</font> our <font color="blue">stockholders</font> to replace or remove our current <font color="blue">management</font> by     making it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to <font color="blue">replace members</font> of our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Because our board of <font color="blue">directors</font> is responsible for appointing the     members of our <font color="blue">management</font> team, these <font color="blue">provisions could</font> in turn affect any     <font color="blue">attempt by</font> our <font color="blue">stockholders</font> to <font color="blue">replace current members</font> of our <font color="blue">management</font>     team</td>
    </tr>
    <tr>
      <td>These provisions include:          •                 <font color="blue">authorizing</font> the issuance of  &amp;quote blank check &amp;quote  <font color="blue">preferred stock</font> that                 could be issued by our board of <font color="blue">directors</font> to increase the number                 of <font color="blue">outstanding shares</font> or change the balance of <font color="blue">voting control</font>                 and thwart a <font color="blue">takeover attempt</font>;          •                 <font color="blue">prohibiting cumulative voting</font> in the election of <font color="blue">directors</font>,                 which  would  otherwise  allow for less than a majority of                 <font color="blue">stockholders</font> to elect director <font color="blue">candidates</font>;          •                 prohibiting stockholder action by written consent, thereby                 requiring all <font color="blue">stockholder actions</font> to be taken at a meeting of                 our <font color="blue">stockholders</font>;          •                 <font color="blue">eliminating</font>  the ability of <font color="blue">stockholders</font> to call a special                 meeting of <font color="blue">stockholders</font>; and          •                 <font color="blue">establishing advance</font> notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for                 election to the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that                 can be acted <font color="blue">upon at stockholder meetings</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to Section 203 of the <font color="blue">Delaware </font>General     Corporation Law, <font color="blue">which generally prohibits</font> a <font color="blue">Delaware </font><font color="blue">corporation from</font>     engaging in any of a <font color="blue">broad range</font> of business <font color="blue"><font color="blue">combinations</font> with</font> an interested     stockholder for a period of <font color="blue">three years following</font> the <font color="blue">date on which</font> the     <font color="blue">stockholder became</font> an <font color="blue">interested stockholder</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">provision could</font> have the     effect of delaying or preventing a change of control, whether or not it is     desired by or <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>the foregoing,     the three year <font color="blue">moratorium</font> imposed on business <font color="blue">combinations</font> by Section 203     will not apply to Warburg because, prior to the <font color="blue">date on which</font> Warburg became     an <font color="blue">interested stockholder</font>, our board of <font color="blue">directors</font> approved the <font color="blue">transaction</font>     which resulted in Warburg becoming an <font color="blue">interested stockholder</font></td>
    </tr>
    <tr>
      <td>However, in     <font color="blue"><font color="blue">connection</font> with</font> its purchase of <font color="blue">Exchangeable Preferred</font>, Warburg <font color="blue">entered into</font>     a <font color="blue">standstill agreement agreeing</font> not to pursue, for four years, certain     <font color="blue">activities</font> the purpose or effect of which may be to chance or influence the     control of Allos</td>
    </tr>
    <tr>
      <td>We have adopted a <font color="blue">stockholder rights</font> plan that may discourage, delay     or prevent a merger or <font color="blue">acquisition</font> that is <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In May 2003, our board of <font color="blue">directors</font> adopted a <font color="blue">stockholder rights</font>     plan that may have the effect of discouraging, delaying or preventing a     merger  or <font color="blue">acquisition</font> of us that is <font color="blue">beneficial</font> to our <font color="blue">stockholders</font> by     diluting the ability of a <font color="blue">potential acquirer</font> to acquire us</td>
    </tr>
    <tr>
      <td>Pursuant to the     terms  of  our  plan,  when  a  person  or group, <font color="blue">except under certain</font>     <font color="blue">circumstances</font>, acquires 15prca or more of our outstanding <font color="blue">common stock</font> or 10     business days after <font color="blue">announcement</font> of a tender or <font color="blue">exchange offer</font> for 15prca or     more of our outstanding <font color="blue">common stock</font>, the rights (except those rights held     by the person or group who has acquired or announced an offer to acquire 15prca     or more of our outstanding <font color="blue">common stock</font>) would generally become exercisable     for  shares  of  our <font color="blue">common stock</font> at a discount</td>
    </tr>
    <tr>
      <td>In addition, the existence     of the plan <font color="blue">itself may deter</font> a <font color="blue">potential acquirer</font> from acquiring us</td>
    </tr>
    <tr>
      <td>As a     result,  either by operation of the plan or by its <font color="blue">potential deterrent</font>     effect, mergers and <font color="blue">acquisition</font>s of us that our <font color="blue">stockholders</font> may consider in     their <font color="blue">best interests may</font> not occur</td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________               <font color="blue">Because Warburg </font>owns a substantial percentage of our outstanding     <font color="blue">common stock</font>, we amended the <font color="blue">stockholder rights</font> plan in <font color="blue"><font color="blue">connection</font> with</font>     Warburgapstas purchase of the <font color="blue">Exchangeable Preferred</font> to provide that Warburg and     its <font color="blue">affiliates</font> will be exempt from the <font color="blue">stockholder rights</font> plan, unless     Warburg and its <font color="blue">affiliates</font> become, without our prior consent, the <font color="blue">beneficial</font>     owner of more than 44prca of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Under the <font color="blue">stockholder rights</font>     plan, our <font color="blue">Board of Directors </font>has express authority to amend the rights plan     without <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> has been and <font color="blue">may continue</font> to     be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that an <font color="blue">active trading market</font> for our <font color="blue">common stock</font>     will exist at any time</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> has been and is likely to be     highly  volatile and could be subject to <font color="blue">wide fluctuations</font> in price in     response  to  various  factors,  many of which are beyond our control,     including:          •                 actual or anticipated results of our <font color="blue"><font color="blue">clinical trial</font>s</font>;          •                 actual or anticipated <font color="blue"><font color="blue">regulatory</font> approval</font>s or non-approvals of                 our <font color="blue">product <font color="blue">candidates</font></font>, including EFAPROXYN, or of competing                 <font color="blue">product <font color="blue">candidates</font></font>;          •                 changes  in  laws or <font color="blue"><font color="blue">regulations</font> applicable</font> to our product                 <font color="blue">candidates</font>;          •                 changes in the expected or <font color="blue">actual timing</font> of our <font color="blue">development</font>                 programs;          •                 actual or anticipated <font color="blue">variations</font> in quarterly operating results;          •                 <font color="blue">announcement</font>s  of  <font color="blue">technological</font>  <font color="blue">innovations by us</font> or our                 <font color="blue">competitors</font>;          •                 changes in financial estimates or <font color="blue">recommendations by securities</font>                 analysts;          •                 <font color="blue">conditions</font> or trends in the bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font>                 <font color="blue">industries</font>;          •                 changes in the <font color="blue">market valuations</font> of similar companies;          •                 <font color="blue">announcement</font>s by us of <font color="blue">significant</font> <font color="blue">acquisition</font>s, strategic                 partnerships, joint ventures or <font color="blue">capital commitments</font>;          •                 <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>;          •                 disputes or other <font color="blue">development</font>s relating to <font color="blue">proprietary rights</font>,                 including patents, <font color="blue">litigation</font> matters and our ability to obtain                 <font color="blue">patent protection</font> for our <font color="blue">technologies</font>;          •                 <font color="blue">development</font>s  <font color="blue">concerning</font>  any  research  and  <font color="blue">development</font>,                 <font color="blue">manufacturing</font>, and marketing <font color="blue">collaboration</font>s;          •                 sales of large blocks of our <font color="blue">common stock</font>;          •                 sales of our <font color="blue">common stock</font> by our executive officers, <font color="blue">directors</font>                 and five percent <font color="blue">stockholders</font>; and          •                 economic and other <font color="blue">external factors</font>, including <font color="blue">disasters</font> or                 crises</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, the <font color="blue">Nasdaq National Market     </font>and the market for <font color="blue">technology</font> companies in particular have experienced     <font color="blue">extreme price</font> and <font color="blue">volume fluctuations</font> that have often been unrelated or     <font color="blue">disproportionate</font> to the operating performance of those companies</td>
    </tr>
    <tr>
      <td>Further,     there has <font color="blue">been particular <font color="blue">volatility</font></font> in the <font color="blue">market price</font>s of securities of     bio<font color="blue">technology</font> and <font color="blue">life sciences companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and industry     <font color="blue">factors may seriously harm</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>, regardless     of our operating performance</td>
    </tr>
    <tr>
      <td>In the past, following periods of <font color="blue">volatility</font>     in the market, securities class-<font color="blue">action <font color="blue">litigation</font></font> has <font color="blue">often been instituted</font>     <font color="blue">against companies</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font>, if instituted against us, could result     in substantial costs and diversion of <font color="blue">management</font>apstas attention and resources</td>
    </tr>
    <tr>
      <td>32       _________________________________________________________________               We  are required to recognize stock-based <font color="blue">compensation</font> expense     relating to <font color="blue"><font color="blue">employee stock</font> options</font> and <font color="blue">stock purchases under</font> our Employee     Stock  Purchase  Plan,  and the amount of expense we recognize may not     <font color="blue">accurately</font> reflect the value of our share-based payment awards</td>
    </tr>
    <tr>
      <td>Further, the     <font color="blue">recognition</font> of stock-based <font color="blue">compensation</font> expense will cause our net losses to     increase and may cause the <font color="blue">trading price</font> of our <font color="blue">common stock</font> to fluctuate</td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>1, 2006, we adopted Statement of Financial Accounting     Standards   ( &amp;quote SFAS &amp;quote )   Nodtta 123  (<font color="blue">Revised  </font>2004),  Share-Based  Payment     ( &amp;quote SFAS 123R &amp;quote ),  which  requires  the  <font color="blue">measurement</font>  and  <font color="blue">recognition</font> of     <font color="blue">compensation</font> expense for all stock-based <font color="blue">compensation</font> <font color="blue">based on</font> estimated     <font color="blue"><font color="blue">fair value</font>s</font></td>
    </tr>
    <tr>
      <td>As a result, our operating results for the <font color="blue">first quarter</font> of     2006  and  for  future  periods  <font color="blue">will contain</font> a charge for stock-based     <font color="blue">compensation</font> related to <font color="blue"><font color="blue">employee stock</font> options</font> and <font color="blue"><font color="blue">employee stock</font> purchases</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">application</font> of SFAS 123R requires the use of an option-pricing model to     determine the <font color="blue">fair value</font> of share-based payment awards</td>
    </tr>
    <tr>
      <td>This de<font color="blue">termination</font>     of  fair  value  is <font color="blue">affected by</font> our stock price as well as <font color="blue">assumptions</font>     regarding  a  number of <font color="blue">highly complex</font> and <font color="blue">subjective variables</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>variables  include,  but  are not limited to, our expected stock price     <font color="blue">volatility</font> over the term of the awards, and actual and projected employee     <font color="blue">stock option exercise behaviors</font></td>
    </tr>
    <tr>
      <td>Option-pricing models were developed for     use  in estimating the value of <font color="blue">traded options</font> that have no vesting or     hedging <font color="blue">restrictions</font> and are <font color="blue">fully transferable</font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">employee stock</font>     options have <font color="blue">certain characteristics</font> that are <font color="blue">significant</font>ly different from     traded  options, and because changes in the subjective <font color="blue">assumptions</font> can     <font color="blue">materially</font> affect the estimated value, in <font color="blue">management</font>apstas opinion the existing     <font color="blue">valuation models may</font> not provide an accurate measure of the <font color="blue">fair value</font> of     our  <font color="blue"><font color="blue">employee stock</font> options</font></td>
    </tr>
    <tr>
      <td>Although the <font color="blue">fair value</font> of <font color="blue">employee stock</font>     options  is determined in <font color="blue"><font color="blue">accordance</font> with</font> SFAS 123R and other relevant     <font color="blue">accounting pronouncements using</font> an option-pricing model, that value may not     be <font color="blue">indicative</font> of the <font color="blue">fair value</font> observed in a willing buyer/willing seller     market <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>We expect that our adoption of SFAS 123R will have a material impact     on our <font color="blue">financial statements</font> and results of <font color="blue">operations</font> and this <font color="blue">will continue</font>     to be the case for <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effect that our     stock-based <font color="blue">compensation</font> expense will have on the <font color="blue">trading price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we do not progress in our <font color="blue">programs as</font> anticipated, our stock     <font color="blue">price could decrease</font></td>
    </tr>
    <tr>
      <td>For  planning purposes, we estimate the timing of a variety of     clinical, <font color="blue">regulatory</font> and other <font color="blue">milestones</font>, such as when a <font color="blue">certain product</font>     candidate will enter clinical <font color="blue">development</font>, when a <font color="blue">clinical trial</font> will be     completed or when an <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> will be filed</td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font>of our estimates are included in this report</td>
    </tr>
    <tr>
      <td>Our estimates are <font color="blue">based on</font>     information available to us as of the date of this report and a variety of     <font color="blue">assumptions</font></td>
    </tr>
    <tr>
      <td>Many of the underlying <font color="blue">assumptions</font> are outside of our control</td>
    </tr>
    <tr>
      <td>If  <font color="blue">milestones</font>  are not achieved when we estimated that they would be,     <font color="blue">investors could</font> be <font color="blue">disappointed</font>, and our <font color="blue">stock price may decrease</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font>sales of <font color="blue">shares may impact</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">stockholders</font> sell substantial amounts of our <font color="blue">common stock</font>,     the <font color="blue">market price</font> of our <font color="blue">common stock</font> may decline</td>
    </tr>
    <tr>
      <td>These <font color="blue">sales also might</font>     make it more <font color="blue">difficult</font> for us to <font color="blue">sell equity</font> or equity-related securities in     the future at a time and price that we consider <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>We are unable     to predict the effect that sales may have on the <font color="blue">then prevailing market</font>     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Pursuant to a Registration Rights Agreement     entered  <font color="blue">into between us</font> and the purchasers of <font color="blue">Exchangeable Preferred</font>,     <font color="blue">beginning on</font> March 4, 2007, the purchasers of <font color="blue">Exchangeable Preferred</font> will be     entitled to <font color="blue">certain registration rights with respect</font> to the shares of common     stock that were <font color="blue">issued upon exchange</font> of the <font color="blue">Exchangeable Preferred</font></td>
    </tr>
  </tbody>
</table>